Sugi Predict

Sugi Predict / Compounds / SCHEMBL16656118

SCHEMBL16656118

SCHEMBL16656118

Cc1cc2c(F)c(O)ccc2n1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.42
▸ CASP1 P29466 2/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ DHFR P00374 1/20 0.40
▸ ABCB11 O95342 1/20 0.35
▸ ESR1 P03372 2/20 0.35
▸ ESR2 Q92731 2/20 0.35
▸ AR P10275 1/20 0.34
▸ KDM4E B2RXH2 5/20 0.33
▸ HPGD P15428 4/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ BCHE P06276 2/20 0.33
▸ ACHE P22303 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29434887 1.00 HSD17B10 (0.42) HSD17B10CASP1CASP7DHFRABCB11
SCHEMBL22434879 0.81 CASP1 (0.45) HSD17B10CASP1CASP7DHFRKDM4E
SCHEMBL16441211 0.78 CASP1 (0.42) HSD17B10CASP1CASP7DHFRESR1
SCHEMBL16441210 0.75 HSD17B10 (0.41) HSD17B10CASP1CASP7DHFRKDM4E
SCHEMBL12278203 0.73 HSD17B10 (0.52) HSD17B10CASP1CASP7DHFRKDM4E
SCHEMBL18000284 0.73 MAPT (0.46) HSD17B10CASP1CASP7DHFRKDM4E
SCHEMBL2453234 0.73 ABCB11 (0.36) ABCB11
SCHEMBL18052954 0.73 HSD17B10 (0.38) HSD17B10ABCB11KDM4EHPGDALDH1A1
SCHEMBL18052973 0.72 AR (0.31) AR
SCHEMBL17170037 0.71 CASP1 (0.38) HSD17B10CASP1CASP7DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109503686-B Novel nucleoside phosphoramidate compounds and uses thereof 南京圣和药业股份有限公司 2022-03-11 — — CN disclosed
CN-108314697-B Novel nucleoside phosphoramidate compounds and uses thereof 南京圣和药业股份有限公司 2021-05-07 — — CN disclosed
CN-108546277-B Novel nucleoside phosphoramidate compounds and uses thereof 南京圣和药业股份有限公司 2021-05-07 — — CN disclosed
US-9963480-B2 Nucleoside phosphoramidate compound and use thereof NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2018-05-08 — — US disclosed
US-20150361123-A1 NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) 2015-12-17 — — US disclosed
EP-2940031-A1 NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) 2015-11-04 — — EP disclosed
WO-2015057963-A1 FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361123-A1 NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF PNP, NUDT1, SLC28A1 HSD17B10 2705/4885CASP1 795/4885CASP7 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.